News & Updates
Showing Endocrinology articles
Showing
NVAMD risk tied to semaglutide no different from other antidiabetes medications
The risk of neovascular age-related macular degeneration (NVAMD) associated with the use of semaglutide is similar to that with other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or non-GLP-1 RAs among adults with type 2 diabetes (T2D), suggests a study.
Weight loss lowers MACE, T2D risks in women, but weight regain reduces benefits
Healthy premenopausal women with overweight who lose weight through diet with or without aerobic or resistance exercise show a significant reduction in the risks of major adverse cardiovascular events (MACE) and type 2 diabetes (T2D). However, such risks have rebounded with weight regain.
Depression may elevate CVD and all-cause death risks in patients with T2D
Depression is associated with greater risks of incident cardiovascular disease (CVD) and all-cause mortality in patients with type 2 diabetes (T2D), a population-based mediation analysis of 0.5 million Chinese people has shown.
CGM initiation reduces hospitalizations for acute diabetes events
In an observational study, the rates of hospitalizations for acute diabetes events (ADEs) decreased following the initiation of the FreeStyle Libre (FSL) continuous glucose monitoring (CGM) system in adults with type 2 diabetes (T2D).
Retatrutide poised to be the next weight-loss option for T2D with obesity
In the phase III TRIUMP-2 trial, retatrutide improves glycaemic control and reduces body weight in adults with type 2 diabetes (T2D) who are overweight or have obesity, potentially expanding weight-loss options for this population.
